Remove 2022 Remove Biosimilars Remove HIV Treatment and Prevention Agents
article thumbnail

ADA 2025: Advances in Type 2 Diabetes Management With Tirzepatide

Pharmacy Times

The presentation emphasized early intervention and personalized treatment plans in managing type 2 diabetes, shifting from "treating to failure" to "treating to target." It is not indicated for type 1 diabetes and carries a boxed warning for thyroid C-cell tumors, with unknown risk in humans.

article thumbnail

Pharma’s post-pandemic launch performance problem: what’s the prognosis?

pharmaphorum

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. The initial pandemic lockdowns prevented many patients from seeing doctors face-to-face.

article thumbnail

Contents

RX Note

Soft Contact Lenses - A basic overview Red Eye - Discussion on few possible conditions Styes - Warm compresses are the mainstay of treatment Eye Floaters - It is not often treated, except in severe cases.